Makers Labs.

When is the next results date for Makers Labs.?

No Upcoming Board Meetings

What does Makers Labs. do?

Makers Laboratories Ltd manufactures pharmaceutical formulations and drug intermediates, classified as a Micro Cap company. As of March 2025, it reported net sales of 34 Cr and a market cap of Rs 95 Cr.

Overview:<BR>Makers Laboratories Ltd is engaged in the manufacture of pharmaceutical formulations and drug intermediates, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History:<BR>The company was incorporated in the State of Maharashtra in 1984 and commenced business on 21st July of that year. It underwent a status change with the amalgamation of Makers Drugs & Food Products Ltd. on 1st April 1993. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 34 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 95 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 12.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: 0.06<BR>- Return on Equity: 11.76%<BR>- Price to Book: 1.36<BR><BR>Contact Details:<BR>Address: 54 D Kandivli Industrial Estate, Charkop Kandivli (West) Mumbai Maharashtra : 400067<BR>Tel: 91-22-2868 8544<BR>Email: investors@makerslabs.com<BR>Website: http://www.makerslabs.com

Has Makers Labs. declared dividend?

Makers Laboratories Ltd has declared a 10% dividend, amounting to 1 per share, but the dividend yield is 0%. While the company has shown significant price returns over various periods, dividends have not contributed to overall returns recently.

Makers Laboratories Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1<BR>- Ex-date: 01 Aug 19<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -1.64%, the dividend return was 0%, resulting in a total return of -1.64%.<BR><BR>For the 1-year period, the price return was 40.63%, the dividend return was 0%, leading to a total return of 40.63%.<BR><BR>Over the 2-year period, the price return was 54.5%, with a dividend return of 0%, culminating in a total return of 54.5%.<BR><BR>In the 3-year period, the price return was 10.17%, the dividend return was 0%, resulting in a total return of 10.17%.<BR><BR>During the 4-year period, the price return was -29.09%, with a dividend return of 0%, leading to a total return of -29.09%.<BR><BR>For the 5-year period, the price return was 292.08%, the dividend return was 0%, resulting in a total return of 292.08%.<BR><BR>Overall, while Makers Laboratories Ltd has declared a dividend, the dividend yield remains at 0%, indicating that dividends have not contributed to returns in recent periods. The total returns show significant variability, with particularly strong performance over the 5-year period.

Who are the peers of the Makers Labs.?

Peers of Makers Labs. include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Ind-Swift, Biofil Chemicals, Achyut Healthcar, Godavari Drugs, and Onyx Biotec. Makers Labs. has below-average management risk and growth compared to its peers, with a 1-year return of 30.42%.

Peers: The peers of Makers Labs. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Ind-Swift, Biofil Chemicals, Achyut Healthcar, Godavari Drugs, and Onyx Biotec.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs., while Average management risk is found at Biofil Chemicals and Godavari Drugs. Below Average management risk is noted for Makers Labs., Achyut Healthcar, and Ind-Swift. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs., while Below Average growth is seen at Makers Labs., Divi's Lab., Torrent Pharma, Achyut Healthcar, and Ind-Swift. The Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs., while it is Good for Torrent Pharma, Average for Biofil Chemicals and Godavari Drugs, and Below Average for Makers Labs., Achyut Healthcar, and Ind-Swift.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Ind-Swift has the lowest at -19.94%. Makers Labs. has a 1-year return of 30.42%, which is significantly higher than Ind-Swift but lower than Divi's Lab. Additionally, the six-month returns are negative for Ind-Swift, Biofil Chemicals, Achyut Healthcar, and Godavari Drugs.

What is the technical trend for Makers Labs.?

As of June 5, 2025, Makers Labs shows a mildly bullish trend primarily supported by the weekly MACD and Bollinger Bands, despite some caution from daily moving averages and no clear signals from the RSI or Dow Theory.

As of 5 June 2025, the technical trend for Makers Labs has changed from sideways to mildly bullish. The weekly MACD is mildly bullish, supported by a bullish stance in both the weekly and monthly Bollinger Bands. The KST also indicates a mildly bullish trend on the weekly and bullish on the monthly. However, the daily moving averages are mildly bearish, which adds some caution to the overall outlook. The RSI shows no signal on both weekly and monthly time frames, and Dow Theory indicates no trend in either time frame. Overall, the current stance is mildly bullish, driven primarily by the MACD and Bollinger Bands.

Who are in the management team of Makers Labs.?

As of March 2023, the management team of Makers Labs includes R K P Verma (Chairman), Dipti Shah, Vishal Jain (Independent Directors), Prashant Godha (Non-Executive Director), Saahil U Parikh, Nilesh Jain (Executive Directors), and Surbhi Sharma (Company Secretary). They collectively oversee the company's governance and operations.

As of March 2023, the management team of Makers Labs includes the following individuals:<BR><BR>1. R K P Verma - Chairman & Independent Director<BR>2. Dipti Shah - Independent Non-Executive Director<BR>3. Vishal Jain - Independent Non-Executive Director<BR>4. Prashant Godha - Non-Executive & Non-Independent Director<BR>5. Saahil U Parikh - Non-Independent Executive Director<BR>6. Nilesh Jain - Non-Independent Executive Director<BR>7. Surbhi Sharma - Company Secretary & Compliance Officer<BR><BR>These members play various roles within the company, contributing to its governance and operational management.

Who are the top shareholders of the Makers Labs.?

The top shareholder of Makers Labs is Kaygee Investments Private Limited with a 17.38% stake, followed by public shareholder Tanvi Jignesh Mehta at 2.18%. Individual investors own 31.01% of the company, with no mutual funds or foreign institutional investors currently holding shares.

The top shareholders of Makers Labs include Kaygee Investments Private Limited, which holds the highest stake at 17.38%. The majority of the shares are held by promoters, and there are no pledged promoter holdings. In terms of public shareholders, Tanvi Jignesh Mehta is the largest, holding 2.18%. Additionally, individual investors collectively own 31.01% of the company. There are currently no mutual funds or foreign institutional investors (FIIs) holding shares in Makers Labs.

How big is Makers Labs.?

As of 24th July, Makers Laboratories Ltd has a market capitalization of 89.00 Cr, with recent net sales of 120.75 Cr and a net profit of 7.49 Cr. Shareholder's funds are 70.51 Cr, and total assets are valued at 147.95 Cr.

As of 24th July, Makers Laboratories Ltd has a market capitalization of 89.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 120.75 Cr and a Net Profit of 7.49 Cr.<BR><BR>For the latest annual period ending March 2025, the Shareholder's Funds amounted to 70.51 Cr, while Total Assets were valued at 147.95 Cr.

How has been the historical performance of Makers Labs.?

Makers Labs has shown fluctuating performance over the past five years, with net sales increasing to 120.75 Cr in March 2025, and a significant recovery in profitability, reporting a profit after tax of 10.91 Cr. However, the company faces challenges with negative cash flow of -4.00 Cr in March 2025.

Answer:<BR>The historical performance of Makers Labs shows a fluctuating trend in net sales and profitability over the past five years.<BR><BR>Breakdown:<BR>Makers Labs reported net sales of 120.75 Cr in March 2025, an increase from 104.39 Cr in March 2024 and 101.28 Cr in March 2023, but a decline from 126.63 Cr in March 2022. The total operating income mirrored this trend, reaching 120.75 Cr in March 2025. The company's total expenditure, excluding depreciation, was 112.36 Cr in March 2025, up from 103.34 Cr in March 2024, leading to an operating profit (PBDIT) of 8.39 Cr, a significant recovery from 1.05 Cr in the previous year. However, the operating profit margin (excluding other income) was 6.95% in March 2025, compared to 1.01% in March 2024. Profit before tax improved to 13.41 Cr in March 2025, recovering from a loss of 3.92 Cr in March 2024, while profit after tax was 10.91 Cr, a turnaround from a loss of 4.81 Cr the previous year. The consolidated net profit for March 2025 was 7.49 Cr, compared to a loss of 6.26 Cr in March 2024. The company's total assets decreased to 147.95 Cr in March 2025 from 161.26 Cr in March 2024, and total liabilities also fell to 147.95 Cr from 161.26 Cr. Cash flow from operating activities was negative at -4.00 Cr in March 2025, contrasting with a positive cash flow of 0.00 Cr in March 2024. Overall, while Makers Labs has shown signs of recovery in sales and profitability, it continues to face challenges in cash flow management.

Is Makers Labs. overvalued or undervalued?

As of November 10, 2025, Makers Labs. is considered overvalued with a PE ratio of -4693.22, unfavorable comparisons to peers like Sun Pharma and Cipla, and a significant year-to-date stock decline of 34% versus the Sensex's gain of 6.91%.

As of 10 November 2025, the valuation grade for Makers Labs. has moved from very attractive to very expensive. This indicates a significant shift in the company's perceived value, suggesting that it is currently overvalued. The company's PE ratio stands at an alarming -4693.22, while its EV to EBITDA is 8.94 and EV to Sales is 0.66, which are concerning figures in the context of its financial health.<BR><BR>In comparison to its peers, Makers Labs. is positioned unfavorably against companies like Sun Pharma. Inds., which has a PE ratio of 35.15 and an EV to EBITDA of 10.64, and Cipla, which boasts a PE ratio of 22.45 and an EV to EBITDA of 5.67. The stark contrast in these ratios highlights the overvaluation of Makers Labs. Furthermore, the company's stock has underperformed the Sensex significantly over various periods, with a year-to-date decline of 34.00% compared to the Sensex's gain of 6.91%. Overall, the evidence strongly supports that Makers Labs. is overvalued in the current market.

Are Makers Laboratories Ltd latest results good or bad?

Makers Laboratories Ltd's latest results show a significant quarterly profit improvement, with a net profit of ₹0.94 crores and a 28.82% increase in net sales. However, concerns remain due to an 84.86% year-on-year decline in profits for the nine-month period and a weak return on equity of 2.20%, suggesting caution for investors regarding long-term sustainability.

Makers Laboratories Ltd's latest results present a mixed picture. On one hand, the company reported a consolidated net profit of ₹0.94 crores for Q3 FY26, which is a significant improvement from a loss of ₹0.12 crores in the previous quarter. This marks a dramatic sequential increase of 883.33%. Additionally, net sales reached ₹35.67 crores, reflecting a year-on-year growth of 28.82%, and the operating margin improved to 11.66%, the highest in seven quarters.<BR><BR>However, despite these positive quarterly results, there are significant concerns. The consolidated profits for the nine-month period ending December 2025 have plummeted by 84.86% year-on-year, raising doubts about the sustainability of the recent improvements. Furthermore, the company's return on equity (ROE) remains weak at 2.20%, indicating poor capital efficiency.<BR><BR>Overall, while the quarterly results show some positive trends, the underlying issues with profitability and capital efficiency suggest that the company's long-term outlook remains challenging. Investors should approach with caution, as the recent improvements may not be indicative of a sustainable turnaround.

Should I buy, sell or hold Makers Laboratories Ltd?

Which are the latest news on Makers Labs.?

Why is Makers Laboratories Ltd falling/rising?

As of 19-May, the stock price of Makers Laboratories Ltd is declining, currently at 155.60, reflecting a broader trend of underperformance with a total drop of 2.75% over the last two days and a negative return of 2.14% over the past week. Despite a strong year-to-date performance of +31.70%, the stock has seen a year-over-year decline of 5.90%.

As of 19-May, the stock price of Makers Laboratories Ltd is falling, currently at 155.60, which reflects a decrease of 4.1 points or 2.57%. This decline is part of a broader trend, as the stock has underperformed its sector by 3.17% today and has experienced a consecutive fall over the last two days, resulting in a total drop of 2.75% during this period. <BR><BR>In terms of recent performance, the stock has shown a negative return of 2.14% over the past week, while the benchmark Sensex has gained 0.86%. Additionally, the stock has fallen 1.33% over the past month, even as the Sensex has decreased by 4.19%. Despite a strong year-to-date performance of +31.70%, the stock has seen a year-over-year decline of 5.90%. <BR><BR>Today's trading activity indicates a lack of investor participation, with delivery volume on 18 May plummeting by 92.98% compared to the 5-day average. The stock also traded closer to its intraday low of Rs 154, suggesting a bearish sentiment among investors. Overall, these factors contribute to the current downward trend in the stock price of Makers Laboratories Ltd.